20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw
- 1 March 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 357 (9260) , 934-935
- https://doi.org/10.1016/s0140-6736(00)04219-7
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- In vivo dynamics and pathogenicity of wild-type and resistant Hepatitis B virus during long-term lamivudine monotherapy — a clinical noteJournal of Clinical Virology, 2000
- Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir In vitro do not lead to reduction of the closed circular DNAHepatology, 2000
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strainsJournal of General Virology, 1992